Chemoradiotherapy for locally advanced pancreatic cancer

The Lancet Oncology

Volumn 14, Issue 4, 2013, Pages 269-270

  Diener, Markus K ^a   Combs, Stephanie E ^a   Büchler, Markus W ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; GEMCITABINE;

CANCER RADIOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LETTER; MEDICAL DECISION MAKING; METHODOLOGY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS RESECTION; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY CONTROL; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH SUBJECT; SAMPLE SIZE; SYSTEMATIC ERROR; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; PANCREATIC NEOPLASMS;

EID: 84875767861     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70091-3     Document Type: Letter

References (9)

1. Hartwig W, Werner J, Büchler MW Prognosis of resected pancreatic cancer: is the refined resection margin status dispensable?. Langenbecks Arch Surg 2012, 397:859-860.
2. Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol 2013, published online March 5. http://dx.doi.org/10.1016/S1470-2045(13)70021-4.
3. Diener MK, Simon T, Büchler MW, Seiler CM Prognosis of resected pancreatic cancer: is the refined resection margin status dispensable? Surgical evaluation and knowledge transfer-methods of clinical research in surgery. Langenbecks Arch Surg 2012, 397:1193-1199.
4. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006, 13:1035-1046.
5. Habermehl D, Kessel K, Welzel T, et al. Neoadjuvant chemoradiation with gemcitabine for locally advanced pancreatic cancer. Radiat Oncol 2012, 7:28.
6. Zhu C-P, Shi J, Chen Y-X, Xie W-F, Lin Y Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother Oncol 2011, 99:108-113.
7. Habermehl D, Brecht IC, Bergmann F, et al. Chemoradiation in patients with isolated recurrent pancreatic cancer-therapeutical efficacy and probability of re-resection. Radiat Oncol 2013, 8:27.
8. Fairchild A, Collette L, Hurkmans CW, et al. Do results of the EORTC dummy run predict quality of radiotherapy delivered within multicentre clinical trials?. Eur J Cancer 2012, 48:3232-3239.
9. Yovino S, Poppe M, Jabbour S, et al. Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers. Int J Radiat Oncol Biol Phys 2011, 79:158-162.